These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 2795135)
1. Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin. McKenna DJ; Peroutka SJ J Neurosci; 1989 Oct; 9(10):3482-90. PubMed ID: 2795135 [TBL] [Abstract][Full Text] [Related]
2. 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes. Teitler M; Leonhardt S; Weisberg EL; Hoffman BJ Mol Pharmacol; 1990 Nov; 38(5):594-8. PubMed ID: 2233696 [TBL] [Abstract][Full Text] [Related]
3. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes. Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334 [TBL] [Abstract][Full Text] [Related]
4. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist. Pranzatelli MR Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895 [TBL] [Abstract][Full Text] [Related]
5. Evidence for distinct 5-hydroxytryptamine2 binding site subtypes in cortical membrane preparations. Pierce PA; Peroutka SJ J Neurochem; 1989 Feb; 52(2):656-8. PubMed ID: 2911036 [TBL] [Abstract][Full Text] [Related]
6. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. Lyon RA; Davis KH; Titeler M Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649 [TBL] [Abstract][Full Text] [Related]
7. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353 [TBL] [Abstract][Full Text] [Related]
8. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Hoyer D; Engel G; Kalkman HO Eur J Pharmacol; 1985 Nov; 118(1-2):13-23. PubMed ID: 2935410 [TBL] [Abstract][Full Text] [Related]
9. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand. Titeler M; Lyon RA; Davis KH; Glennon RA Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239 [TBL] [Abstract][Full Text] [Related]
10. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. Heuring RE; Peroutka SJ J Neurosci; 1987 Mar; 7(3):894-903. PubMed ID: 2951504 [TBL] [Abstract][Full Text] [Related]
12. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. McKenna DJ; Repke DB; Lo L; Peroutka SJ Neuropharmacology; 1990 Mar; 29(3):193-8. PubMed ID: 2139186 [TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with (+/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain. McKenna DJ; Nazarali AJ; Himeno A; Saavedra JM Neuropsychopharmacology; 1989 Mar; 2(1):81-7. PubMed ID: 2803482 [TBL] [Abstract][Full Text] [Related]
14. R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype. Wang SS; Mathis CA; Peroutka SJ Psychopharmacology (Berl); 1988; 94(3):431-2. PubMed ID: 3357926 [TBL] [Abstract][Full Text] [Related]
15. Identification of spinal 5-HT1C binding sites in the rat: characterization of [3H]mesulergine binding. Pranzatelli MR; Murthy JN; Pluchino RS J Pharmacol Exp Ther; 1992 Apr; 261(1):161-5. PubMed ID: 1560361 [TBL] [Abstract][Full Text] [Related]
16. [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Branchek T; Adham N; Macchi M; Kao HT; Hartig PR Mol Pharmacol; 1990 Nov; 38(5):604-9. PubMed ID: 2233697 [TBL] [Abstract][Full Text] [Related]
17. Differential inactivation and G protein reconstitution of subtypes of [3H]5-hydroxytryptamine binding sites in brain. Stratford CA; Tan GL; Hamblin MW; Ciaranello RD Mol Pharmacol; 1988 Oct; 34(4):527-36. PubMed ID: 3139989 [TBL] [Abstract][Full Text] [Related]
18. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Sleight AJ; Stam NJ; Mutel V; Vanderheyden PM Biochem Pharmacol; 1996 Jan; 51(1):71-6. PubMed ID: 8534270 [TBL] [Abstract][Full Text] [Related]
20. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Choudhary MS; Craigo S; Roth BL Mol Pharmacol; 1993 May; 43(5):755-61. PubMed ID: 8388989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]